Page last updated: 2024-11-04

tegafur and Chemotherapy-Induced Febrile Neutropenia

tegafur has been researched along with Chemotherapy-Induced Febrile Neutropenia in 1 studies

Chemotherapy-Induced Febrile Neutropenia: FEVER accompanied by a significant reduction in NEUTROPHIL count associated with CHEMOTHERAPY.

Research Excerpts

ExcerptRelevanceReference
"Patients with stage III gastric cancer who underwent D2 gastrectomy were enrolled."3.01Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer. ( Hirahara, N; Hyakudomi, R; Ishitobi, K; Kaji, S; Matsubara, T; Tajima, Y; Takai, K; Uchida, Y; Yamamoto, T, 2021)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Hirahara, N1
Matsubara, T1
Kaji, S1
Yamamoto, T1
Hyakudomi, R1
Takai, K1
Ishitobi, K1
Uchida, Y1
Tajima, Y1

Trials

1 trial available for tegafur and Chemotherapy-Induced Febrile Neutropenia

ArticleYear
Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer.
    BMC cancer, 2021, Oct-01, Volume: 21, Issue:1

    Topics: Adenocarcinoma; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy

2021